Susquehanna International Group’s Immuneering IMRX Stock Holding History

Susquehanna International Group’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$556K	Sell	105,507 -1,965	-2%	-$10.1K	﹤0.01%	9383
2025 Q4	$707K	Buy	+107,472	New	+$690K	﹤0.01%	8005
2024 Q3	–	Sell	-88,756	Closed	-$114K	–	12464
2024 Q2	$114K	Buy	+88,756	New	+$146K	﹤0.01%	10927
2024 Q1	–	Sell	-10,603	Closed	-$77.9K	–	12708
2023 Q4	$77.9K	Buy	+10,603	New	+$70.6K	﹤0.01%	11496
2023 Q2	–	Sell	-57,949	Closed	-$563K	–	12577
2023 Q1	$563K	Buy	57,949 +12,949	+29%	+$73.5K	﹤0.01%	8274
2022 Q4	$218K	Buy	+45,000	New	+$399K	﹤0.01%	9905

Other funds holding IMRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OCM

Occam Crest Management Darien, Connecticut $165M AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group's IMRX Position: Q1 2026 in Review

Susquehanna International Group reduced its Immuneering (IMRX) stake by 1.8% in Q1 2026, selling an estimated $10.1K and leaving 105,507 shares worth $556K. The position accounts for ﹤0.01% of the portfolio, ranked #9383.

Susquehanna International Group first reported a position in IMRX in Q4 2022 and has held it in 6 quarters since. The position peaked at $707K in Q4 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

Susquehanna International Group held 105,507 shares of Immuneering worth $556K as of Q1 2026.
Susquehanna International Group sold 1,965 Immuneering shares in Q1 2026, an estimated $10.1K.
Immuneering made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9383 holding.
Susquehanna International Group first reported a position in Immuneering in Q4 2022 and has held it in 6 quarters since.
Susquehanna International Group's Immuneering position peaked at $707K in Q4 2025.
95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.